Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with suspicion of non-invasive bladder cancer indicated for a transuretheral resection of the bladder~* Above 18 years~* Written informed consent obtained~Exclusion Criteria:~* Gross hematuria. (Note: Gross hematuria is defined as a heavy bladder bleed resulting in marked amounts of blood in the urine, which may interfere with fluorescence cystoscopy. Where the bleed is light, the patient should not be excluded if in the investigator's opinion, rinsing during cystoscopy will alleviate the possible interference with fluorescence cystoscopy).~* Patient with porphyria.~* Known allergy to hexyl aminolevulinate hydrochloride or a similar compound.~* Participation in other clinical studies with investigational drugs either concurrently or within the last 30 days.~* Pregnant or breast-feeding (all women of child-bearing potential must document a negative serum or urine pregnancy test at screening and use the contraceptive pill or intrauterine device (IUD) during the treatments and for at least one month thereafter).~* Conditions associated with a risk of poor protocol compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hexvix cystoscopy group (Type: ACTIVE_COMPARATOR): None
- White light (Type: OTHER): Standard White light cystoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).